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Clinical oncology relies increasingly on biomedical imaging, with anatomical imaging, especially 
using CT and 1H-MRI, forming the mainstay of patient assessment, from diagnosis to treatment 
monitoring. However, the need for further improvements in specificity and sensitivity, coupled 
with imaging techniques that are reaching their limit of clinically attainable spatial resolution, 
has resulted in the emergence and growing use of imaging techniques with additional functional 
readouts, such as 18FDG-PET and multiparametric MRI. These techniques add a new dimension to 
our understanding of the biological behavior of tumors, allowing a more personalized approach to 
patient management.
An important functional imaging target in cancer is metabolism. PET measurements of 
18Fluorodeoxyglucose uptake (18FDG-PET), a 18F-labeled glucose analog, and 1H-MRS measure-
ments, have both been used to investigate tumor metabolism for diagnostic purposes. However, 
clinical applications of MRS have been hampered by low sensitivity and consequently low 
spatial and temporal resolution (1). Nuclear spin hyperpolarization of 13C-labeled substrates, 
using dynamic nuclear polarization (DNP), which radically increases the sensitivity of these 
substrates to detection by 13C MRS (2), has created a renewed interest in MRS measurements of 
tissue metabolism. Successful translation of this technique to the clinic was achieved recently 
with measurements of [1-13C]pyruvate metabolism in prostate cancer (3) (see Figure  1). 
We explore here the potential clinical roles for metabolic imaging with hyperpolarized 
[1-13C]pyruvate.
DYnAMiC nUCLEAR pOLARiZATiOn
Dynamic nuclear polarization, which can increase the signal-to-noise ratio in the solution-state 
13C MR experiment by 104- to 105-fold (4), has enabled in vivo imaging of various metabolites 
and their enzymatic conversion into other species, as well as metabolic fluxes in central metabolic 
pathways, such as glycolysis (5–7) and the tricarboxylic acid cycle (8–10). The principle limita-
tion of the technique is the short half-life of the polarization; for [1-13C]pyruvate in vivo, this is 
typically between 30 and 40 s, which means that the hyperpolarized signal will last for 2–3 min. 
Therefore, the substrate, whose metabolism is to be imaged, must be transferred promptly from 
the polarizer, injected intravenously, and then transit quickly via the circulation to the tissue 
of interest, where it should be taken up and metabolized rapidly (11, 12). To date, numerous 
molecules, in addition to 13C-labeled pyruvate, have been successfully hyperpolarized and their 
metabolism imaged, including [1,4-13C2]fumarate, as a marker of cell necrosis (13, 14); [U-2H, 
Abbreviations: 18FDG, 18Fluorodeoxyglucose; MRS, magnetic resonance spectroscopy; MRSI, magnetic resonance spectro-
scopic imaging; PET, positron emission tomography.
FiGURE 1 | imaging prostate cancer with hyperpolarized  
[1-13C]pyruvate. The T2-weighted image of a patient with biopsy-proven 
bilateral prostate cancer showed only a unilateral decrease in signal intensity. 
However, the metabolic image ([1-13C]lactate/[1-13C]pyruvate ratio) detected 
disease on both the right and left sides of the prostate. Reproduced from 
Nelson et al. (3) with permission.
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U-13C]glucose for assessment of glycolytic and pentose phosphate 
pathway activities and for detecting early treatment response 
(7); 13C-labeled bicarbonate for in vivo mapping of pH (15); and 
13C-labeled urea as a marker of perfusion (16), among others 
(13,  16–18). Despite initial interest in vascular imaging (19–21), 
the main focus has been on imaging metabolism in tumors (13, 
17, 22) and cardiac tissue (23–27).
pYRUVATE
Pyruvate is an important intermediate in many biochemical 
pathways (28). As an end product of glycolysis, pyruvate can be 
reduced by NADH to generate lactate, in the readily reversible 
reaction catalyzed by lactate dehydrogenase, or transaminated 
by glutamate, in the reversible reaction catalyzed by alanine 
aminotransferase (ALT), to form alanine. In tissues with high 
levels of mitochondrial activity, such as heart muscle, pyruvate 
may be irreversibly decarboxylated to form carbon dioxide in 
the reaction catalyzed by the mitochondrial pyruvate dehydro-
genase (PDH) complex (26). Since increased aerobic glycolysis 
is a well-recognized hallmark of cancer (29, 30), this has made 
it an attractive pathway to probe for diagnostic and treatment 
monitoring purposes (3, 17, 31).
potential Clinical Roles
Preclinical studies have demonstrated that hyperpolarized 
[1-13C]pyruvate is a promising probe for oncological imaging, 
with increased lactate labeling observed in tumors as compared 
to normal tissues (31, 32). The substrate has the potential to 
be used in many steps of patient management. A recent study 
demonstrated the potential of hyperpolarized [1-13C]pyruvate 
as an imaging biomarker for early detection and secondary 
screening of pancreatic cancer, where a decrease in the hyper-
polarized [1-13C]alanine/[1-13C]lactate ratio was observed in 
the progression from precursor lesions to adenocarcinoma (33). 
In another study, [1-13C]pyruvate detected metabolic changes 
prior to tumor formation (34). Additionally, in the first reported 
clinical trial in prostate cancer, increased lactate labeling was 
observed in histologically confirmed areas of disease that 
were not identifiable by conventional 1H-MRI measurements 
(3) (Figure 1). The few studies that have explored the role of 
[1-13C]pyruvate in grading and prognosis, which were in the 
transgenic mouse model of prostate adenocarcinoma (TRAMP), 
have also produced promising results (35, 36). Tumor grading 
by biopsy can sometimes be difficult depending on the accessi-
bility of the organ of interest. Translation of the DNP technique 
to the clinic may allow more accurate targeting of biopsy proce-
dures. Since lactate labeling is increased in regions of hypoxia, 
the technique also has the potential to be used for treatment 
planning in radiotherapy (37, 38). Clinical assessments of 
tumor responses to treatment are still based largely on observed 
changes in tumor size (39). However, this might not always be 
appropriate, particularly for detection of early responses or if 
the drug does not result in tumor shrinkage, for example, in the 
case of antiangiogenic drugs (40, 41). Additionally, treatment 
assessment using 18FDG-PET is difficult in some organs, e.g., 
prostate and brain, due to both low tumor uptake and increased 
background uptake, respectively (40). Evaluation of treatment 
response is likely to be the clinical scenario where hyperpolar-
ized [1-13C]pyruvate will have the most impact, as it could lead 
to immediate changes in clinical management, allowing the 
clinician to change a non-responding patient to a more effec-
tive drug at an early stage (40). Early assessment of treatment 
response could also be used to accelerate the introduction of 
new drugs into the clinic by providing an indication of drug effi-
cacy in early stage clinical trials. In support of this are numerous 
studies showing early decreases in hyperpolarized 13C-labeled 
exchange between injected [1-13C]pyruvate and the endogenous 
lactate pool in a range of cancer models following treatment 
with cytotoxic chemotherapy (17, 42), targeted drugs (43–45), 
and radiotherapy (41, 46, 47).
There is as yet no direct evidence to support the suggestion 
that residual disease/recurrence can be identified by increased 
lactate labeling. However, observations of increased lactate labe-
ling in areas of disease and following disease progression (3, 33) 
make this likely. There is, however, evidence that hyperpolarized 
[1-13C]pyruvate can be used to assess normal tissue toxicity, with 
an increase in the [1-13C]lactate/[1-13C]pyruvate ratio occurring 
in radiation-induced lung injury (48, 49).
ADVAnTAGES OF METABOLiC iMAGinG 
WiTH [1-13C]pYRUVATE
Advantages Compared to 18FDG-pET
Metabolic imaging of cancer in the clinic has principally 
been with 18FDG-PET, which has been used to stage tumors 
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and to assess treatment response. Despite its high  sensitivity 
and capability to provide whole-body images, the use of 
ionizing radiation is a drawback, limiting its application 
in children and women of reproductive age, and when 
multiple investigations are needed, for example, as might 
be required for guiding treatment in an individual patient. 
A similar clinical role can be envisaged for [1-13C]pyruvate 
as has been established for 18FDG-PET. Both techniques can 
be used to detect increased glycolytic flux (50) and have 
been shown to be comparably sensitive in detecting tumor 
response to treatment (51). However, since hyperpolarized 
[1-13C]pyruvate effectively detects lactate accumulation (11), 
a defining feature of cancer metabolism, i.e., the failure to 
oxidize pyruvate in the presence of oxygen and reduce it 
instead to lactate (the “Warburg Effect”), this means that 
hyperpolarized [1-13C]pyruvate may be more specific for 
detecting cancer than 18FDG-PET. The latter detects only 
elevated levels of glucose uptake, which is a feature of many 
normal tissues and cancer, for example, the brain. The speci-
ficity of cancer detection by hyperpolarized [1-13C]pyruvate 
may be confounded, however, by the presence of hypoxia, 
which will also lead to lactate accumulation and increased 
lactate labeling (38). Another drawback of imaging with 
hyperpolarized [1-13C]pyruvate is that the short half-life of 
the polarization precludes whole-body imaging.
Advantages Compared to 1H MRS
1H-MR spectroscopy and spectroscopic imaging measure-
ments of tissue metabolite profiles are label-free and have 
found some applications, for example, in identifying dif-
ferent types of brain tumor (52). A notable example is the 
detection of 2-hydroxyglutarate, which can be used to iden-
tify glioblastomas with isocitrate dehydrogenase mutations 
(IDH) (53). 1H MRSI has also proved to be important in the 
prostate, where it can improve the specificity of detection 
and determination of tumor extent when combined with 
other MR imaging sequences (54). However, detectable 
metabolites are present in only millimolar concentrations, 
as compared to tissue water protons, which are present at 
~80M, which results in long data acquisition times and 
limited spatial resolution. In addition, data processing can 
be more complex and the biochemical information provided 
may be unfamiliar to many clinicians, which has limited rou-
tine clinical application. Moreover, 1H MR spectroscopy and 
spectroscopic images of metabolite profiles provide a static 
picture of tumor metabolism. On the other hand, imaging 
with hyperpolarized 13C-labeled substrates provides dynamic 
metabolic flux information in the form of images that can 
be acquired at relatively high spatial and temporal resolu-
tions and therefore should provide an improved assessment 
of tumor behavior. Additionally, coinjection of different 
hyperpolarized substrates could also provide additional 
functional information in the same acquisition, e.g., pyruvate 
for assessing glycolytic activity and urea for assessing tumor 
perfusion (55).
COMBininG METABOLiC iMAGinG WiTH 
HYpERpOLARiZED [1-13C]pYRUVATE 
WiTH nEW TECHnOLOGiES
pET-MRi
This is an emerging combined imaging modality with sig-
nificant potential for clinical assessment of cancer patients (56). 
Simultaneous PET-MR measurements with hyperpolarized 
13C- and 18F-labeled substrates would allow a multiparametric 
assessment of the primary lesion and its metastases in a single 
imaging session, which potentially could be used to identify 
imaging-based phenotypes that have prognostic value and which 
may give a more specific readout of treatment response. For exam-
ple, PET measurements of 18FDG uptake assess just the first three 
steps in tumor glucose metabolism, i.e., delivery via the blood-
stream, uptake on the glucose transporters, and phosphorylation 
and trapping in the reaction catalyzed by hexokinase. 13C MRSI 
measurements of the exchange of hyperpolarized 13C-labeled 
exchange between injected [1-13C]pyruvate and the endogenous 
lactate pool again assess delivery via the bloodstream and effec-
tively the last two steps in the glycolytic pathway, i.e., the steps 
catalyzed by lactate dehydrogenase and the plasma membrane 
monocarboxylate transporters. Therefore, by combining 18FDG-
PET and hyperpolarized [1-13C]pyruvate measurements, we may 
be able to assess flux in the entire glycolytic pathway, for example, 
increased mitochondrial oxidation of pyruvate may have no effect 
on 18FDG uptake but could decrease 13C labeling of lactate. There 
are other PET probes of tumor metabolism that could also be 
used alongside hyperpolarized [1-13C]pyruvate, and which could 
provide complementary information. These include 11C-acetate, 
as a marker of fatty acid synthesis, and labeled glutamine, which 
can be used to assess glutaminolysis; both of which are upregu-
lated in tumor cells (57, 58). These PET probes may be especially 
useful in tumors where 18FDG is ineffective, e.g., in prostate 
tumors (59) and in gliomas (60), and where the corresponding 
hyperpolarized 13C-labeled probes are limited. For example, the 
metabolism of hyperpolarized [1-13C]acetate has been detected 
in vivo (61); however, the short lifetime of the hyperpolarization 
means that it could not be used to monitor fatty acid synthesis, 
where PET studies with [1-11C]acetate in animal tumor models 
have shown that it can take over 60 min before there is substantial 
incorporation into the fatty acid pool (62). In the case of [5-13C]
glutamine, a relatively short hyperpolarization lifetime and slow 
metabolism (63) has precluded imaging in vivo (64).
Liquid Biopsies
Blood and urine biomarkers, obtained from “liquid biopsies,” are 
also evolving, providing information in a non-invasive way allied 
to the advantages of collection simplicity and relatively low cost. 
Many body fluid biomarkers have been reported for different 
types of cancer; however, few have become established in the 
clinic, usually because they lack specificity. A recent promising 
example is a panel of three urine biomarkers for early detection of 
pancreatic cancer (65). Rapid advances in DNA sequencing tech-
nology have allowed somatic mutations present in tumor cells to 
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be detected and tracked in blood-borne circulating tumor DNA 
(ctDNA). These fragments of DNA, which have been detected 
with most types of cancer, have been demonstrated to have poten-
tial roles in early detection, staging, and in detecting response to 
therapy and acquired resistance to treatment (66, 67). Although 
measurements with hyperpolarized 13C-labeled cell substrates 
and these new circulating biomarkers are still their infancy it 
seems likely that they will provide complementary information, 
for example, in the assessment of tumor heterogeneity.
COnCLUSiOn AnD FUTURE DiRECTiOnS
Imaging with hyperpolarized 13C-labeled cell substrates has the 
potential to become a powerful tool in many steps of clinical 
evaluation, allowing a more personalized approach to treatment. 
The first clinical trial established the feasibility of imaging human 
tumors with hyperpolarized [1-13C]pyruvate. Since this substrate 
can be used to assess glycolysis, which is upregulated in many 
tumors, then this should make it a very general tool for onco-
logical imaging in the clinic. Despite the biological insights that 
imaging with hyperpolarized 13C-labeled substrates promises to 
deliver in the clinic, it will nevertheless have to prove itself against 
established and emerging clinical techniques, demonstrating that 
it can provide unique information that changes clinical practice.
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